Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.

Recent Treatment Guideline Updates in Follicular Lymphoma

Sameh R. Gaballa, MD, Moffitt Cancer Center;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

July 14th 2023

Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 10th 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 10th 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 3rd 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 3rd 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

June 26th 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

June 26th 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Overview of Relapsed/Refractory DLBCL and Management Strategies

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

June 19th 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

Joanna M. Rhodes, MD, MSCE;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Yucai Wang, MD, PhD, Mayo Clinic;Hayder M. Saeed, MD, Moffitt Cancer Center

June 19th 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.